Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer

✍ Scribed by Qiu Li; Yu-Quan Wei; Yan-Jun Wen; Xia Zhao; Ling Tian; Li Yang; Yong-Qiu Mao; Bing Kan; Yang Wu; Zhen-Yu Ding; Hong-Xin Deng; Jiong Li; Yan Luo; Hong-Li Li; Qiu-Ming He; Jing-Mei Su; Fei Xiao; Chun-Hua Zou; Chun-Hua Fu; Xing-Jiang Xie; Tao Yi; Guang-Hong Tan; Lian Wang; Jing Chen; Jian Liu; Zhen-Nan Gao

• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: French
• Weight: 328 KB
• Volume: 112
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.20276

✦ Synopsis

Abstract

Vesicular stomatitis virus (VSV) has been shown to replicate rapidly in vitro and kill selectively a variety of tumor cell lines. The present study was designed to determine whether gemcitabine potentiates the antitumor activity of VSV in vitro and in vivo. A549 human lung adenocarcinoma cells and LLC Lewis lung carcinoma cells were treated with VSV (0.1–10 plaque‐forming units per cell) plus gemcitabine (20 nM to 20 μM). Mice bearing A549 or LLC were treated with VSV (5 × 10^4^ to 1 × 10^8^ plaque‐forming units) daily for 5 days plus gemcitabine (5–125 mg/kg/day) once every 3 days for 4 times. Induction of apoptosis and effects on growth inhibition were assessed. The lung cancer cells treated with VSV plus gemcitabine displayed the apparently increased apoptotic cells compared with treatment with VSV or gemcitabine alone. The combined treatment with VSV plus gemcitabine induced the apparent antitumor activity with complete regression of the established lung cancer in both A549 and LLC lung cancer models and augmented the induction of apoptosis in lung cancer cells in vivo as well. This study suggests that the combined treatment with VSV plus gemcitabine may augment the induction of apoptosis in lung cancer cells in vitro and in vivo, and that the augmented antitumor activity in vivo may result from the increased induction of apoptosis in lung cancer cells. The present findings may be of importance to the further exploration of the potential application of this combined approach in the treatment of lung cancer. © 2004 Wiley‐Liss, Inc.